A prognostic systemic inflammation score (SIS) in patients with advanced intrahepatic cholangiocarcinoma

被引：0
作者：
M. Maßmann
J. Treckmann
P. Markus
B. Schumacher
D. Albers
S. Ting
B. Mende
J. Roehrle
I. Virchow
V. Rosery
K. Laue
G. Zaun
K. Kostbade
M. Pogorzelski
K. W. Schmid
H. Baba
J. T. Siveke
A. Paul
H. U. Schildhaus
M. Schuler
M. Wiesweg
S. Kasper
机构：
[1] University Hospital Essen,West German Cancer Center, Department of Medical Oncology
[2] University Hospital Essen,West German Cancer Center, Department of General, Visceral and Transplant Surgery
[3] Elisabeth Hospital Essen,Department of General Surgery and Traumatology
[4] Elisabeth Hospital Essen,Department of Gastroenterology
[5] University Hospital Essen,West German Cancer Center, Institute of Pathology Essen
[6] University Hospital Essen,Central Pharmacy
[7] Partner Site University Hospital Essen,German Cancer Consortium (DKTK)
[8] University Hospital Essen,Bridge Institute of Experimental Tumor Therapy, West German Cancer Center
[9] University Duisburg-Essen,Medical Faculty
[10] German Cancer Consortium (DKTK,Division of Solid Tumor Translational Oncology
[11] Partner Site Essen) and German Cancer Research Center,undefined
[12] DKFZ,undefined
来源：
Journal of Cancer Research and Clinical Oncology | 2023年 / 149卷
关键词：
Intrahepatic cholangiocellular carcinoma; Chemotherapy; Advanced disease; Inflammation; Systemic-inflammatory response parameters; Prognosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：5085 / 5094
页数：9
相关论文
共 173 条
[1]  
Abou-Alfa GK(2020)Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study Lancet Oncol 21 796-807
[2]  
Macarulla T(2017)Cholangiocarcinoma: current knowledge and new developments Gut Liver 11 13-26
[3]  
Javle MM(2011)Hallmarks of cancer: the next generation Cell 144 646-674
[4]  
Kelley RK(2014)Second-line chemotherapy in advanced biliary cancer: a systematic review Ann Oncol 25 2328-2338
[5]  
Lubner SJ(2020)Advanced Intrahepatic cholangiocarcinoma: post hoc analysis of the ABC-01, -02 and -03 clinical trials J Natl Cancer Inst 112 200-210
[6]  
Adeva J(2021)Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial Lancet Oncol 22 690-701
[7]  
Cleary JM(2019)Comparative performance of inflammation-based prognostic scores in patients operated for intrahepatic cholangiocarcinoma Cancer Manag Res 11 9107-9119
[8]  
Catenacci DV(2021)Combined systemic inflammation score (SIS) correlates with prognosis in patients with advanced pancreatic cancer receiving palliative chemotherapy J Cancer Res Clin Oncol 147 579-591
[9]  
Borad MJ(2017)Epidemiology of hepatocellular carcinoma and intrahepatic cholangiocarcinoma Cancer Control 24 1073274817729245-1073274817729245
[10]  
Bridgewater J(2014)Neutrophil/lymphocyte ratio as a prognostic factor in biliary tract cancer Eur J Cancer 50 1581-1589
12345678910